Are you Dr. Pullarkat?
Join over one million U.S. Physicians, Nurse Practitioners and PAs, already on Doximity.
- Gain access to free telehealth tools, such as our "call shielding" and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
You already have 91 invites waiting! - Read the latest clinical news, personalized to your specialty.
Office
1500 Duarte Rd
Duarte, CA 91010Phone+1 626-256-4673Fax+1 626-389-3061
Summary
- Dr. Vinod Pullarkat, MD is an oncologist in Duarte, California. He is currently licensed to practice medicine in California and Utah. He is affiliated with City of Hope Comprehensive Cancer Center, Keck Hospital of USC, and USC Norris Comprehensive Cancer Center.
Education & Training
University of Southern California/LAC+USC Medical CenterFellowship, Hematology, 1998 - 2000- University of Southern California/LAC+USC Medical CenterFellowship, Medical Oncology, 1997 - 1998
New York-Presbyterian Brooklyn Methodist HospitalResidency, Internal Medicine, 1994 - 1997
Medical College and Hospital KolkataClass of 1992
Certifications & Licensure
CA State Medical License 1997 - 2025
UT State Medical License 1996 - 1998- American Board of Internal Medicine Hematology
Clinical Trials
- Myelodysplastic Syndromes (MDS) Event Free Survival With Iron Chelation Therapy Study Start of enrollment: 2010 Mar 22
- Combined Tretinoin and Arsenic Trioxide for Patients With Newly Diagnosed Acute Promyelocytic Leukemia Followed by Risk-Adapted Postremission Therapy Start of enrollment: 2011 Jul 01
- Phase II Study to Evaluate Overall Response in Patients With Higher Risk Myelodysplastic Syndromes (MDS) Treated With Azacitidine With or Without Deferasirox. Start of enrollment: 2014 Sep 11
Publications & Presentations
PubMed
- Lower-intensity CPX-351 plus venetoclax induction for adults with newly diagnosed AML unfit for intensive chemotherapy.Geoffrey L Uy, Vinod Pullarkat, Praneeth Baratam, Robert K Stuart, Roland B Walter
Blood Advances. 2024-12-24 - 1 citationsImpact of prior inotuzumab ozogamicin treatment on brexucabtagene autoleucel outcomes in adults with B-cell ALL.Ibrahim Aldoss, Gregory W Roloff, Rawan Faramand, Noam E Kopmar, Chenyu Lin
Blood Advances. 2024-12-10 - 3 citationsExpert consensus on the management of pharmacodynamic breakthrough-hemolysis in treated paroxysmal nocturnal hemoglobinuria.David Dingli, Carlos De Castro Iii, Jamie Koprivnikar, Austin Kulasekararaj, Jaroslaw Maciejewski
Hematology. 2024-12-01
Authored Content
- Azacitidine and Venetoclax in Previously Untreated Acute Myeloid LeukemiaAugust 2020
- Azacitidine and Venetoclax in Previously Untreated Acute Myeloid LeukemiaAugust 2020
- Azacitidine and Venetoclax in Previously Untreated Acute Myeloid LeukemiaAugust 2020
- Azacitidine and Venetoclax in Previously Untreated Acute Myeloid LeukemiaAugust 2020
- Join now to see all
Press Mentions
Improving Outcomes in Older Patients with Newly Diagnosed ALLMay 9th, 2019
Excess Iron in MDSOctober 7th, 2016
Novartis Gets USFDA Nod for Fabhalta for Adults with Paroxysmal Nocturnal HemoglobinuriaDecember 8th, 2023- Join now to see all
